EGFR-sparing HER2 kinase inhibitor
approved in met. HER2+ BC incl. w/ brain met.
from optimization of known TKIs
Mol. Cancer Ther., Apr. 1, 2020
Array / Cascadian Tx / Seattle Genetics
tucatinib
Tucatinib is the third approved HER2 kinase inhibitor (after lapatinib and neratinib), but differentiates itself due to its selectivity against the closely related EGFR, which is hypothesized to be a…